Allergan PLCFind Ratings Reports
ALLERGAN PLC's gross profit margin for the second quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ALLERGAN PLC has weak liquidity. Currently, the Quick Ratio is 1.00 which shows a lack of ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
During the same period, stockholders' equity ("net worth") has remained virtually unchanged only decreasing by 1.85% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY17||Q2 FY16|
|Net Sales ($mil)||4007.4||3684.8|
|Net Income ($mil)||-725.9||-501.7|
|Balance Sheet||Q2 FY17||Q2 FY16|
|Cash & Equiv. ($mil)||5825.9||506.6|
|Total Assets ($mil)||124734.8||132619.1|
|Total Debt ($mil)||30238.3||39581.7|
|Profitability||Q2 FY17||Q2 FY16|
|Gross Profit Margin||88.17||88.92|
|Return on Assets||9.56||3.33|
|Return on Equity||-5.29||-3.21|
|Debt||Q2 FY17||Q2 FY16|
|Share Data||Q2 FY17||Q2 FY16|
|Shares outstanding (mil)||334.1||395.8|
|Div / share||0.7||0.0|
|Book value / share||225.14||193.64|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2143246.0||2318001.0|
HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 0.90 indicates a significant discount versus the S&P 500 average of 3.11 and a significant discount versus the industry average of 16.19. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ALLERGAN PLC proves to trade at a discount to investment alternatives within the industry.
|AGN NM||Peers 29.15||AGN 42.88||Peers 25.28|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AGN's P/E is negative making this valuation measure meaningless.
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AGN is trading at a significant premium to its peers.
|AGN 11.38||Peers 15.58||AGN NA||Peers 0.62|
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.
AGN is trading at a discount to its peers.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AGN 0.90||Peers 16.19||AGN -86.85||Peers 28.90|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AGN is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, AGN is expected to significantly trail its peers on the basis of its earnings growth rate.
|AGN 4.49||Peers 10.21||AGN 6.40||Peers 7.17|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AGN is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
AGN trails its peers on the basis of sales growth